opdivohcp.com


Tags Whois Backlink & Rankings Speed Safety Headers Similar Sites Keywords H Tags
Tags Whois Rank Speed Safety Headers Similar Sites Keywords H Tags

opdivohcp.com Website Info

opdivohcp.com (Find information about OPDIVO® (nivolumab) treatment, dosing schedules, safety, MOA, and resources. Please see Indications and Important Safety Information.) was registered first at 2014-03-03 23:39:28. DNS looks Active and website looks Accessable. opdivohcp.com Website SEMRush Rank is 1,159,104. According to Google, website speed score is 0/100 and . Website looks safe for children. We detected the website language as en.
opdivohcp.com


opdivohcp.com Website Tags

Domain Status:
✓ Active
Is Site Accessable?:
✓ Yes
SSL(https):
✓ Yes
Accessable Url:
https://www.opdivohcp.com
Title:
OPDIVO® (nivolumab) | Healthcare Professional Website
Description:
Find information about OPDIVO® (nivolumab) treatment, dosing schedules, safety, MOA, and resources. Please see Indications and Important Safety Information.
Categories :
Health, Medicine
External Links:
39
Internal Links:
81
Canonical URL:
https://www.opdivohcp.com/
Language:
en
XML Sitemap:
✓ Yes
robots.txt:
✓ Yes https://www.opdivohcp.com/robots.txt
Favicon:
✓ Yes

opdivohcp.com Domain & Whois Details

Refresh
Domain Create Date:
2014-03-03 23:39:28
Domain Age:
11 years, 4 months, 0 days
Domain Expire Date:
2024-03-03T23:39:28Z
Domain Last Update Date:
2024-03-03T23:39:28Z
Domain Owner:
http://cscdbs.com - CSC Corporate Domains, Inc. -
Server Type:
Apache
Nameservers:
NS1.BMS.COM - NS2.BMS.COM - NS3.BMS.COM - NS4.BMS.COM -
Hosting Location:
Country:United States, City:Redwood City, Isp:Incapsula Inc, Org:Incapsula Inc
IP:
45.60.150.161

opdivohcp.com Backlinks & Rankings

SEMRush Rank:
1,159,104
Semrush Rank is a proprietary score that lets you find the domains that are getting the most traffic from organic search.
SEMRush Traffic:
783
Number of users expected to visit the website during the following month.
SEMRush Costs:
9,204
Estimated price of organic keywords in Google AdWords.
SEMRush URL Links:
137
Number of links to URL according to SemRush.
SEMRush Website Links:
137
Number of links to the website according to SemRush.
SEMRush Domain Links:
7,459
Number of links to SemRush Domain.
SEMRush Keywords In Top 100:
412
Number of keywords where site in Google's organic search top 100.

opdivohcp.com Social Media

Facebook Comments:
3
Facebook Shares:
16
Facebook Reactions:
8

opdivohcp.com Website Speed (Desktop) Check Now

Speed analysis has not been completed yet. Our system will be checking this website soon.
Site Speed Check(Full)


opdivohcp.com Website Safety

Refresh
Last Check Date:
6/21/2023 6:33:21 PM
Fortiguard:
Medicine
Mcafee Category:
Health
OpenDNS:
BeFirst
Cloudflare DNS:
OK
MyWot Child Safety:
99

opdivohcp.com HTTP Headers

Refresh
Accept-Ranges :
bytes
Cache-Control :
max-age=600,s-maxage=600
Connection :
keep-alive
Content-Security-Policy :
frame-ancestors https://oncologynationsandbox.skipta.com https://oncologynation.com https://clinical
Content-Type :
text/html;charset=utf-8
Date :
Fri, 09 Jun 2023 23:54:28 GMT
Server :
Apache
Set-Cookie :
visid_incap_2893158=YmKBEgqATEG2am6aSLwvArO7g2QAAAAAQUIPAAAAAABMpobKRRnVGkdCWuHr0vK+; expires=Sat, 0
strict-transport-security :
max-age=63072000; includeSubDomains; preload
Transfer-Encoding :
chunked
Vary :
Accept-Encoding,User-Agent
Via :
1.1 c824f42276c55792245504036b5383fa.cloudfront.net (CloudFront)
X-Amz-Cf-Id :
zwWR0PRoJLFlI2ccFSsvGwH7_EBhIFQ3I6rcRZj7wUYawJTPo6wYCw==
X-Amz-Cf-Pop :
JFK50-P3
X-Cache :
Miss from cloudfront
X-Cdn :
Imperva
x-content-type-options :
nosniff
X-Dispatcher :
dispatcher2useast1
X-Dispatcher-Number :
2
X-Frame-Options :
SAMEORIGIN
X-Iinfo :
13-70178643-70178646 NNNN CT(2 6 0) RT(1686354867885 6) q(0 1 1 1) r(1 1) U24
X-Vhost :
publish


opdivohcp.com W3C HTML Validation Check Now

Last Check Date:
5/31/2023 12:00:00 AM
Errors:
4
Warnings:
0
Info:
2
Check Live:
Check opdivohcp.com HTML Errors

opdivohcp.com Similar Sites

Website
Title
Rank
opdivo.com opdivo.com
OPDIVO® (nivolumab)
yervoy.com yervoy.com
OPDIVO® (nivolumab)
38,101,781
pfizermedicalinformation.ca pfizermedicalinformation.ca
Information for Healthcare Professionals | Pfizer Medical Information - Canada
149,077
pfizermedicalinformation.in pfizermedicalinformation.in
Information for Healthcare Professionals | Pfizer Medical Information - India
11,714,734
emplicitihcp.com emplicitihcp.com
EMPLICITI® (elotuzumab) | Healthcare Professional Website
2,062,632
Top opdivohcp.com Alternatives

opdivohcp.com Site Keywords

Healthcare Professional Website
Information for Healthcare Professionals
Locale Keywords
OPDIVO® (nivolumab)

opdivohcp.com Site H Tags

Check Now
h2
OPDIVO IMPORTANT SAFETY INFORMATION
h2
OPDUALAG IMPORTANT SAFETY INFORMATION
h2
Welcome to OPDIVO®
h3
Explore the latest data, approvals, and updates
h3
Severe and Fatal Immune-Mediated Adverse Reactions
h3
Severe and Fatal Immune-Mediated Adverse Reactions
h3
Infusion-Related Reactions
h3
Complications of Allogeneic Hematopoietic Stem Cell Transplantation
h3
Embryo-Fetal Toxicity
h3
Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue
h3
Lactation
h3
Serious Adverse Reactions
h3
Common Adverse Reactions
h3
Clinical Trials and Patient Populations
h3
Infusion-Related Reactions
h3
Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
h3
Embryo-Fetal Toxicity
h3
Lactation
h3
Serious Adverse Reactions
h3
Common Adverse Reactions and Laboratory Abnormalities
h3
Unresectable or Metastatic Melanoma (fixed-dose therapy)
h3
Non-Small Cell Lung Cancer
h3
Advanced Renal Cell Carcinoma
h3
Gastric, Gastroesophageal Junction, or Esophageal Cancers
h3
Melanoma
h3
Urothelial Carcinoma
h3
Unresectable Malignant Pleural Mesothelioma
h3
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck on or After Platinum-Based Ther
h3
Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
h3
MSI-H/dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment With a Fluoropyrimid
h3
Relapsed or Progressed cHL After Autologous HSCT and Brentuximab Vedotin or After 3 or More Lines of
h3
IMPORTANT SAFETY INFORMATION
h4
Summary of Warnings and Precautions for OPDIVO
h4
Summary of Warnings and Precautions for Opdualag
h4
Immune-Mediated Pneumonitis
h4
Immune-Mediated Colitis
h4
Immune-Mediated Hepatitis and Hepatotoxicity
h4
Immune-Mediated Endocrinopathies
h4
Immune-Mediated Nephritis with Renal Dysfunction
h4
Immune-Mediated Dermatologic Adverse Reactions
h4
Other Immune-Mediated Adverse Reactions
h4
Immune-Mediated Pneumonitis
h4
Immune-Mediated Colitis
h4
Immune-Mediated Hepatitis
h4
Immune-Mediated Endocrinopathies
h4
Immune-Mediated Nephritis with Renal Dysfunction
h4
Immune-Mediated Dermatologic Adverse Reactions
h4
Immune-Mediated Myocarditis
h4
Other Immune-Mediated Adverse Reactions


What is SitesDB?

SitesDB is one of the largest databases of websites and domain names on the internet, with over 40 million entries and growing. For more than 12 years, we've been manually verifying and updating website and domain details, combining human expertise with AI-powered systems to ensure the accuracy and relevance of our data.

At SitesDB, we provide in-depth technical and useful information about websites and domains, including:

  • Website meta tags
  • Domain & WHOIS data
  • General backlink and ranking statistics
  • Social media engagement stats
  • Root page speed insights
  • Website content and HTML resources
  • Website safety and security details, sourced from multiple trusted security providers
  • HTTP headers analysis
  • HTML validation reports
  • Lists of similar websites and competitors
  • Website keyword analysis, including top traffic-driving keywords
  • Heading structure (H tags) breakdown
  • Domain variations across different TLDs (Top-Level Domains)

In addition to this data, SitesDB offers a suite of website analysis tools — including Chrome CRUX, Google Lighthouse, and our own AI-enhanced algorithms — to help identify alternative websites, direct competitors, and similar sites, all continuously refined through both automated systems and human review.